The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.
Dominik Paul Modest
Honoraria - Amgen
Other Remuneration - Merck
Ruediger Paul Laubender
Honoraria - Merck KGaA
Research Funding - Merck KGaA
Other Remuneration - Merck
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Martina Stauch
No relevant relationships to disclose
Holger Hass
No relevant relationships to disclose
Hermann F. Dietzfelbinger
No relevant relationships to disclose
Daniel V. Oruzio
No relevant relationships to disclose
Stefan Klein
No relevant relationships to disclose
Klaus Zellmann
No relevant relationships to disclose
Thomas Decker
No relevant relationships to disclose
Mathias Schulze
No relevant relationships to disclose
Wolfgang Abenhardt
No relevant relationships to disclose
Gerhard Puchtler
No relevant relationships to disclose
Herbert W. Kappauf
No relevant relationships to disclose
Johann Mittermueller
No relevant relationships to disclose
Christopher Haberl
No relevant relationships to disclose
Sebastian Stintzing
Honoraria - Merck Serono
Ulrich Robert Mansmann
Research Funding - Merck Serono
Volker Heinemann
Honoraria - Merck Serono
Research Funding - Merck Serono
Other Remuneration - Merck Serono